Market Update Economic Events Directors Deals Commodities Prices News Market Movers

Hvivo inks two contracts with 'leading' global biopharmaceutical company

Monday, 8th October 2018
Hvivo, a clinical development services business, said Monday it had signed two new contracts with a leading global biopharmaceutical company to provide two respiratory syncytial virus human challenge studies.

The two studies were projected to deliver a total of about £9m in revenue, the bulk of which would be recognised in 2019, the company said.

'We are pleased to have signed these two contracts with this global biopharmaceutical company. The recent significant new contract wins reinforce our leading position in human disease models based upon viral and allergen challenge and are a testament to our industry leading RSV-human challenge model. We have the strongest sales pipeline we have had for several years,' said Dr Trevor Phillips, Executive Chairman of hVIVO.

'We remain actively engaged in several discussions with other pharmaceutical companies for contracting studies across our current challenge portfolio, including allergen, asthma, human rhinovirus, influenza and RSV.'

At 8:37am: (LON:HVO) hVIVO Plc share price was +6.5p at 65p

Story provided by

Related Shares: Hvivo

Share Search
Share Search Share Search

Visit the Share Search.
Share Search

Share News
Share News will do their best to ensure the quality of the information displayed on this site, but all information is provided as-is, free of charge. We cannot be held responsible for any loss, material or otherwise, due to incorrect information found here. UK data supplied by NBTrader and Digital Look. Share Prices are at least 15 minutes delayed.